{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:41:39Z","timestamp":1773297699110,"version":"3.50.1"},"reference-count":51,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,1,30]],"date-time":"2009-01-30T00:00:00Z","timestamp":1233273600000},"content-version":"vor","delay-in-days":1978,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2003,9]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>We investigated the effect of the cannabinoid CB<jats:sub>1<\/jats:sub> receptor antagonist, SR 141716, on indomethacin\u2010induced small intestine inflammation and <jats:italic>Escherichia coli<\/jats:italic> lipopolysaccharide (LPS)\u2010induced plasma TNF\u2010<jats:italic>\u03b1<\/jats:italic> (TNF) release in comparison to the cannabinoid CB<jats:sub>2<\/jats:sub> receptor antagonist, SR 144528, in rodents.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In rats, indomethacin induced significant ulcer formation in the small intestine; this was accompanied by an increase in tissue TNF levels and myeloperoxidase (MPO) activity. SR 141716 prevented the ulcers and the rise in TNF levels (ID<jats:sub>50<\/jats:sub> 3.3, 0.4 mg kg<jats:sup>\u22121<\/jats:sup>, respectively) and MPO activity. SR 144528 prevented intestinal ulcers only.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The effect of SR 141716 against indomethacin\u2010induced ulcers and increase of plasma TNF levels after LPS was also studied in wild\u2010type and CB<jats:sub>1<\/jats:sub> receptor knockout mice. Indomethacin induced intestinal ulcers in mice, but not tissue TNF production and MPO activity. SR 141716 reduced the ulcers to a similar extent in wild\u2010type and CB<jats:sub>1<\/jats:sub> receptor knockout mice. In rats and wild\u2010type mice, but not in CB<jats:sub>1<\/jats:sub> receptor knockout mice, SR 141716 inhibited the LPS\u2010induced increase in plasma TNF levels.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>These findings provide evidence that the indomethacin model of intestinal lesions differs in rat and mouse and support the existence of several mechanisms for the antiulcer activity of SR141716, the most important involving the inhibition of TNF production. The potent anti\u2010inflammatory activity of SR141716 in rodents indicated its potential therapeutic interest in chronic immune\u2010inflammatory diseases.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (2003) <jats:bold>140<\/jats:bold>, 115\u2013122. doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0705412\">10.1038\/sj.bjp.0705412<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0705412","type":"journal-article","created":{"date-parts":[[2003,9,10]],"date-time":"2003-09-10T15:50:23Z","timestamp":1063209023000},"page":"115-122","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Role of cannabinoid CB<sub>1<\/sub> receptors and tumor necrosis factor\u2010<i>\u03b1<\/i> in the gut and systemic anti\u2010inflammatory activity of SR 141716 (Rimonabant) in rodents"],"prefix":"10.1111","volume":"140","author":[{"given":"Tiziano","family":"Croci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Landi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne\u2010Marie","family":"Galzin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Marini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01972748"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00324-5"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701968"},{"key":"e_1_2_7_5_1","first-page":"473","article-title":"Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross\u2010regulation","volume":"55","author":"BOUABOULA M.","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.35.22330"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1993.tb17910.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(76)90527-3"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V60.3.618.618"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704466"},{"key":"e_1_2_7_11_1","unstructured":"CROCI T. LANDI M. MARINI P. RINALDI\u2010CARMONA M.&MANARA L.(2002).Inhibition of TNF\u2010\u03b1production by the cannabinoid CB1receptor antagonist SR141716 may account for its prevention of indomethacin intestinal injury in rats. 2002 Symposium on the Cannabinoids Burlington Vermont International Cannabinoid Research Society. p.120."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702190"},{"key":"e_1_2_7_13_1","first-page":"605","article-title":"Determination and characterization of a cannabinoid receptor in rat brain","volume":"34","author":"DEVANE W.A.","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365529309104012"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1995.tb20780.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.35.040195.003135"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.54.2.161"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-978810"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704293"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00005325"},{"key":"e_1_2_7_21_1","first-page":"736","article-title":"Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid\u2010mediated immune modulation","volume":"42","author":"KAMINSKI N.E.","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1373.2000.22501.x"},{"key":"e_1_2_7_23_1","first-page":"25","article-title":"Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin\u2010induced small intestinal lesions in rats","volume":"50","author":"KONAKA A.","year":"1999","journal-title":"J. Physiol. Pharmacol."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004410000261"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02053-8"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.283.5400.401"},{"key":"e_1_2_7_27_1","unstructured":"LE FUR G. ARNONE M. RINALDI\u2010CARMONA M. BARTH F.&HESHMATI H.(2001).SR141716 a selective antagonist of CB1receptors and obesity. Symposium on the Cannabinoids Burlington Vermont International Cannabinoid Research Society. p.101."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(02)80146-3"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(01)01110-9"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00860-2"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00015-5"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/365061a0"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(99)00286-6"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704327"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.6.859"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00012435"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34242"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.2307\/2531207"},{"key":"e_1_2_7_39_1","first-page":"583","article-title":"Acute in vivo effects of human recombinant tumor necrosis factor","volume":"56","author":"REMICK D.G.","year":"1987","journal-title":"Lab. Invest."},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(97)00213-3"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(94)00773-X"},{"key":"e_1_2_7_42_1","first-page":"644","article-title":"SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor","volume":"284","author":"RINALDI\u2010CARMONA M.","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.122149199"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00437-4"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(00)00307-6"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01477-7"},{"key":"e_1_2_7_47_1","first-page":"136","article-title":"Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti\u2010inflammatory interleukin\u201010 in endotoxemic mice","volume":"293","author":"SMITH S.R.","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01142-6"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3764421"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.12.11.1035"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1063545"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.10.5780"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0705412","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0705412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0705412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T14:39:22Z","timestamp":1697207962000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0705412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["10.1038\/sj.bjp.0705412"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0705412","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9]]},"assertion":[{"value":"2009-01-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}